| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2008: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Research Abstract |
Among advanced gastric cancer patients, recent progress of anti-cancer chemotherapy has increased the number of patients who may be treated by operation after the chemotherapy. To evaluate chemotherapeutic responses of target tissues at molecular level, we prepared tissue microarrays (TMAs) using specimens from operations after chemotherapy. Between 2000 and 2007, 30 advanced gastric cancer patients underwent gastrectomy after chemotherapy including S-1, CDDP, irinotecan, and docetaxel. Chemotherapeutic regimens were grouped as follows (the number of cases) : S-1 alone (5) ; S-1+cisplatin (17) ; irinotecan alone (4) ; docetaxel (3) ; and cisplatin+irinotecan (1). Pathological examinations were performed on TMA for pre-treatment biopsies and post-operative specimens. Immunohistochemical (IHC) examinations were also performed with primary antibodies against proteins including p53, MIB-1, and pancytokeratin. Correlations between either pathological or IHC effect, and RECIST criteria were
… More
evaluated. Correlation between clinical (quotation marks) and histological (Grades) responses were : "Partial Response", Grades 0(4), 1a(5), 1b(1), 2(2) ; "Stable Disease", Grades 0(2), 1a(4), 1b(1), 2(3) ; and "Progressive Disease", Grades 0(0), 1a(4), 1b(0), 2(0). We did not judge "Complete Response" or Grade 3. Comparison of IHC between pre and post chemotherapy, protein expression was decreased by 36.7% in p53, 76.7% in MIB-1, 63.3% in pancytokeratin. TMAs are a useful technology that can observe protein expression of large numbers of specimens simultaneously without losing tissue morphological information. Proteins stained by IHC tend to decrease the staining intensity in samples after chemotherapy although it was not clearly correlated with tissue type or the treatment effect. No significant correlation was seen between RECIST criteria and histological effect of the treatment. Although it is necessary to review more cases using pre-and post-chemotherapeutic specimens from clinical and pathological point of views, it may also suggest that the other chemotherapeutic evaluation criteria that reflect biological as well as clinical responses should be discussed. Less
|
